Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095391 · ClinicalTrials.gov registry record
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
A clinical trial of Acute Kidney Injury and Kidney Diseases, sponsored by FAST BioMedical.
- Completed
- Registry status
- 32
- Enrollment target
- 2
- Study locations
NCT03095391 is a study of Acute Kidney Injury and Kidney Diseases that has completed, run by FAST BioMedical. The registered enrollment target is 32 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03095391, a study of Acute Kidney Injury and Kidney Diseases, has completed, sponsored by FAST BioMedical.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2b, prospective, open-label study designed to evaluate the safety, tolerability, PK, and PD of FAST PV and mGFR Technology in healthy subjects and patients with varying degrees of renal impairment.
Conditions Studied
Interventions
- DEVICE VFI
- DEVICE Iohexol
Study Locations (2)
Alabama
- University of Alabama Birmingham, Division of Nephrology - Birmingham
Texas
- ICON Early Phase Services, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-06-13 |
| Est. Completion | 2017-09-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03095391
The ClinicalTrials.gov registry entry for NCT03095391 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The listed sponsor is FAST BioMedical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which VFI is the first listed.
NCT03095391 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Texas.
Frequently Asked Questions
What is clinical trial NCT03095391 about?
NCT03095391 is a clinical study titled "The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™". This is a Phase 2b, prospective, open-label study designed to evaluate the safety, tolerability, PK, and PD of FAST PV and mGFR Technology in healthy subjects and patients with varying degrees of renal impairment.
What is the current status of trial NCT03095391?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2017-06-13. Estimated completion is 2017-09-20.
What conditions does trial NCT03095391 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Kidney Diseases, Renal Insufficiency, Renal Insufficiency, Chronic, Urologic Diseases.
What interventions are being tested in trial NCT03095391?
The interventions under investigation include: VFI (DEVICE), Iohexol (DEVICE).
Who is sponsoring clinical trial NCT03095391?
This trial is sponsored by FAST BioMedical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03095391 being conducted?
This trial has 2 study locations across Alabama, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.